Host and Viral Genetic Variation in HBV-Related Hepatocellular Carcinoma

Area of Science:

• Hepatology
• Oncology
• Genetics

Background:

• Hepatocellular carcinoma (HCC) is a leading cause of cancer death globally, often linked to chronic Hepatitis B virus (HBV) infection.
• Lack of early detection biomarkers and effective late-stage treatments contribute to HCC's high mortality rate.
• Individual HCC development varies due to HBV factors, host genetics, somatic mutations, and environmental influences.

Purpose of the Study:

• To explore the genetic and molecular factors influencing Hepatocellular carcinoma (HCC) development and progression.
• To identify biomarkers for early diagnosis and prognostic indicators for HCC.
• To understand the role of viral and host genetic variations in HCC tumorigenesis for potential therapeutic targets.

Main Methods:

• Review of genetic associations, including HBV genotypes, host germline variations (e.g., KIF1B, HLA-DQ, STAT4, GRIK1), and somatic mutations (e.g., TERT promoter, CTNNB1, TP53).
• Analysis of Hepatitis B virus (HBV) integration into host genes and the impact of viral protein mutations (e.g., HBx).
• Examination of epigenetic modifications (e.g., ARID2, MLL4) in hepatic tumor tissues.

Main Results:

• HBV genotype C, preS, basic core promoter (BCP), and HBx mutations increase HCC risk.
• Host polymorphisms in KIF1B, HLA-DQ, STAT4, and GRIK1 are associated with altered HBV-related HCC risk.
• Somatic mutations in TERT promoter, CTNNB1, TP53, ARID2, and MLL4 are frequently found in HCC, alongside HBV integration events.

Conclusions:

• Understanding HBV and host variations is crucial for improving early HCC diagnosis and prognosis.
• Somatic mutations driving tumorigenesis offer potential for developing precision treatments for HCC patients.
• Further research into these genetic and molecular alterations can advance HCC management strategies.